Registry following people treated with neurovascular devices for brain conditions
Follows adults treated with devices for brain aneurysms or ischemic stroke.
Plain-language title generated from the registry record
Registry title: Neurovascular Product Surveillance Registry
Key facts
- Where
- Augsburg, Berlin, Bochum, Erfurt, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Munich, and Nuremberg, GermanySee the 11 sites
Where in Germany
- Klinikum AugsburgAugsburg, GermanyNo longer taking part
- Charité Universitätsmedizin Berlin -Campus ChariteBerlin, GermanyNo longer taking part
- Knappschaftskrankenhaus Bochum-Langendreer - UniversitätsklinikBochum, GermanyNo longer taking part
- Helios Klinikum ErfurtErfurt, GermanyNo longer taking part
- Universitätsklinikum ErlangenErlangen, GermanyNo longer taking part
- Alfried Krupp KrankenhausEssen, GermanyNo longer taking part
- Universitätsklinikum FreiburgFreiburg im Breisgau, GermanyTaking people
- Universitätsklinikum Hamburg-EppendorfHamburg, GermanyNo longer taking part
- Universitätsklinikum HeidelbergHeidelberg, GermanyTaking people
- LMU Klinikum der Universität MünchenMunich, GermanyTaking people
- Klinikum Nürnberg - Klinikum Nürnberg SüdNuremberg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medtronic Neurovascular Clinical Affairs
- Trial code
- NCT02988128
- Record updated
- 15 September 2026
- Original description
Post market surveillance registryRead full original descriptionShow less
NeuroVascular Product Surveillance Registry (PSR) Platform
Post market surveillance registry
Inclusion: Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements; Patient has, or is intended to receive or be treated with, an eligible Medtronic product; Patient is consented within the enrollment window of the therapy received, as applicable; Patient is at least 18 years of age at time of enrollment.
Exclusion: Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results; Patient is treated or intended to be treated with an eligible Medtronic Neurovascular product; Patient is currently enrolled in, or plans to enroll in, any concurrent drug/device study that may confound the study results; Additional criteria may be required, refer to cohort-specific Addendum, as applicable, for further guidance; Patient who is, or is expected to be inaccessible for follow-up; Patient with exclusion criteria required by local law; Female patient who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study; For MDT24028 and MDT22032:; General Inclusion Criteria:; Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements; Patient is an adult per local law at time of consent. Medtronic Business Restricted This document is electronically controlled CONFIDENTIAL 056-F275 Rev F Clinical Investigation Plan Template; General Exclusion Criteria:; Patient who may be unable to complete the study follow-up; Patient with any contraindications per the applicable Instructions for Use document; Female patient who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study.
For MDT16056 and MDT17077.